• Kyodo

  • SHARE

Japanese health authorities have been unable to reach a conclusion on the effectiveness of antiviral drug Avigan in treating COVID-19 patients based on the results of clinical testing by its developer, government sources said Wednesday.

The latest assessment by the Pharmaceuticals and Medical Devices Agency will serve as key material for a health ministry review panel that will likely decide on Monday whether to approve the use of Avigan to treat COVID-19 in Japan.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)